Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Payables (2023 - 2025)

Historic Payables for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $848000.0.

  • Artiva Biotherapeutics' Payables fell 3020.58% to $848000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $848000.0, marking a year-over-year decrease of 3020.58%. This contributed to the annual value of $1.1 million for FY2024, which is 8257.33% up from last year.
  • As of Q3 2025, Artiva Biotherapeutics' Payables stood at $848000.0, which was down 3020.58% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Payables ranged from a high of $2.0 million in Q1 2025 and a low of $614000.0 during Q4 2023
  • In the last 3 years, Artiva Biotherapeutics' Payables had a median value of $1.1 million in 2024 and averaged $1.1 million.
  • As far as peak fluctuations go, Artiva Biotherapeutics' Payables soared by 8257.33% in 2024, and later crashed by 3020.58% in 2025.
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Payables stood at $614000.0 in 2023, then skyrocketed by 82.57% to $1.1 million in 2024, then dropped by 24.35% to $848000.0 in 2025.
  • Its Payables stands at $848000.0 for Q3 2025, versus $1.2 million for Q2 2025 and $2.0 million for Q1 2025.